127 related articles for article (PubMed ID: 36250888)
41. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M; Marshall QF; Warrington JM; Premaratne R; Farrel A; Groff D; Li W; di Marco M; Runbeck E; Truong H; Toor JS; Tripathi S; Nguyen S; Shen H; Noel T; Church NL; Weiner A; Kendsersky N; Martinez D; Weisberg R; Christie M; Eisenlohr L; Bosse KR; Dimitrov DS; Stevanovic S; Sgourakis NG; Kiefel BR; Maris JM
Nature; 2021 Nov; 599(7885):477-484. PubMed ID: 34732890
[TBL] [Abstract][Full Text] [Related]
42. A proteome-wide atlas of lysine-reactive chemistry.
Abbasov ME; Kavanagh ME; Ichu TA; Lazear MR; Tao Y; Crowley VM; Am Ende CW; Hacker SM; Ho J; Dix MM; Suciu R; Hayward MM; Kiessling LL; Cravatt BF
Nat Chem; 2021 Nov; 13(11):1081-1092. PubMed ID: 34504315
[TBL] [Abstract][Full Text] [Related]
43. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.
Aschmoneit N; Steinlein S; Kühl L; Seifert O; Kontermann RE
Sci Rep; 2021 Jul; 11(1):13880. PubMed ID: 34230555
[TBL] [Abstract][Full Text] [Related]
44. Acquired Resistance to KRAS
Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
[TBL] [Abstract][Full Text] [Related]
45. Sotorasib for Lung Cancers with
Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R
N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690
[TBL] [Abstract][Full Text] [Related]
46. Selective and noncovalent targeting of RAS mutants for inhibition and degradation.
Teng KW; Tsai ST; Hattori T; Fedele C; Koide A; Yang C; Hou X; Zhang Y; Neel BG; O'Bryan JP; Koide S
Nat Commun; 2021 May; 12(1):2656. PubMed ID: 33976200
[TBL] [Abstract][Full Text] [Related]
47. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
48. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
49. Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States.
Lim S; Khoo R; Juang YC; Gopal P; Zhang H; Yeo C; Peh KM; Teo J; Ng S; Henry B; Partridge AW
ACS Cent Sci; 2021 Feb; 7(2):274-291. PubMed ID: 33655066
[TBL] [Abstract][Full Text] [Related]
50. Bispecific antibodies targeting mutant
Douglass J; Hsiue EH; Mog BJ; Hwang MS; DiNapoli SR; Pearlman AH; Miller MS; Wright KM; Azurmendi PA; Wang Q; Paul S; Schaefer A; Skora AD; Molin MD; Konig MF; Liu Q; Watson E; Li Y; Murphy MB; Pardoll DM; Bettegowda C; Papadopoulos N; Gabelli SB; Kinzler KW; Vogelstein B; Zhou S
Sci Immunol; 2021 Mar; 6(57):. PubMed ID: 33649101
[TBL] [Abstract][Full Text] [Related]
51. Multiplex bead binding assays using off-the-shelf components and common flow cytometers.
Hattori T; Koide A; Panchenko T; Romero LA; Teng KW; Corrado AD; Koide S
J Immunol Methods; 2021 Mar; 490():112952. PubMed ID: 33358997
[TBL] [Abstract][Full Text] [Related]
52. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling.
Fedele C; Li S; Teng KW; Foster CJR; Peng D; Ran H; Mita P; Geer MJ; Hattori T; Koide A; Wang Y; Tang KH; Leinwand J; Wang W; Diskin B; Deng J; Chen T; Dolgalev I; Ozerdem U; Miller G; Koide S; Wong KK; Neel BG
J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33045063
[TBL] [Abstract][Full Text] [Related]
53. KRAS
Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT
N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176
[TBL] [Abstract][Full Text] [Related]
54. T cell-engaging therapies - BiTEs and beyond.
Goebeler ME; Bargou RC
Nat Rev Clin Oncol; 2020 Jul; 17(7):418-434. PubMed ID: 32242094
[TBL] [Abstract][Full Text] [Related]
55. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.
Xue JY; Zhao Y; Aronowitz J; Mai TT; Vides A; Qeriqi B; Kim D; Li C; de Stanchina E; Mazutis L; Risso D; Lito P
Nature; 2020 Jan; 577(7790):421-425. PubMed ID: 31915379
[TBL] [Abstract][Full Text] [Related]
56. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR
Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701
[TBL] [Abstract][Full Text] [Related]
57. Direct Detection and Quantification of Neoantigens.
Wang Q; Douglass J; Hwang MS; Hsiue EH; Mog BJ; Zhang M; Papadopoulos N; Kinzler KW; Zhou S; Vogelstein B
Cancer Immunol Res; 2019 Nov; 7(11):1748-1754. PubMed ID: 31527070
[TBL] [Abstract][Full Text] [Related]
58. Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours.
Lowe KL; Cole D; Kenefeck R; OKelly I; Lepore M; Jakobsen BK
Cancer Treat Rev; 2019 Jul; 77():35-43. PubMed ID: 31207478
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic strategies to target RAS-mutant cancers.
Ryan MB; Corcoran RB
Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
[TBL] [Abstract][Full Text] [Related]
60. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.
Fedele C; Ran H; Diskin B; Wei W; Jen J; Geer MJ; Araki K; Ozerdem U; Simeone DM; Miller G; Neel BG; Tang KH
Cancer Discov; 2018 Oct; 8(10):1237-1249. PubMed ID: 30045908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]